09:48 AM EST - Resverlogix Corp. : has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau. The deal structure involves $50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of $400 million U.S. Resverlogix Corp.
shares T.RVX are trading up $0.22 at $2.91.
